Want to see CH:GALD full AI Analyst Report?
GALD Stock Chart & Stats
CHF171.60
-CHF0.05(-0.03%)
At close: 4:00 PM EDT
CHF171.60
-CHF0.05(-0.03%)
Day’s Range― - ―
52-Week RangeCHF134.70 - CHF188.25
Previous CloseN/A
Volume352.30K
Average Volume (3M)723.83K
Market Cap
CHF37.50B
Enterprise ValueCHF44.67K
Total Cash (Recent Filing)CHF841.26M
Total Debt (Recent Filing)CHF2.70B
Price to Earnings (P/E)47.4
Beta0.86
Next Earnings
Mar 11, 2027EPS Estimate
2.09Next Dividend Ex-DateN/A
Dividend Yield0.22%
Share Statistics
EPS (TTM)4.09
Shares Outstanding237,897,630
10 Day Avg. Volume1,295,434
30 Day Avg. Volume723,833
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF200.60Price Target Upside16.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.82
Revenue Forecast (FY)CHF6.39B
Bulls Say, Bears Say
Bulls Say
High Margins And ProfitabilityConsistently high gross margins and the rise in EBIT margin indicate stronger operating economics and improved profitability. If maintained, this combination can support reinvestment, absorb operating costs, and provide a more durable earnings base across the company’s dermatology segments.
Material DeleveragingThe substantial reduction in leverage and increase in equity have strengthened Galderma’s balance sheet. Lower debt relative to equity should improve financial flexibility, reduce balance-sheet risk, and leave the company better positioned to fund products and growth when conditions soften.
Improved Cash GenerationStrong 2025 operating and free cash flow, alongside FCF tracking earnings reasonably well, indicates improved cash conversion. Greater internally generated funding can support research, launches, debt management, and commercial investment without relying as heavily on external financing.
Bears Say
Uneven Revenue GrowthThe decline in 2025 revenue despite sharply improved earnings shows that top-line momentum has not yet been consistently sustained. Uneven growth can make planning and investment returns less predictable, particularly across Galderma’s multiple product and channel businesses.
Volatile Historical Cash FlowAlthough cash generation improved sharply in 2025, prior weak and negative free cash flow demonstrates that cash conversion has not been consistently proven over a longer period. Continued volatility could constrain funding capacity and make the latest improvement less durable.
Absolute Debt Remains SizableDeleveraging has materially improved the capital structure, but the remaining debt balance is still substantial. If growth weakens or cash generation again becomes volatile, servicing and managing this obligation could limit financial flexibility and compete with investment priorities.
Galderma Group AG News
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF134.70 and its highest was CHF188.25 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF37.50B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Mar 11, 2027 which is in 159 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Jul 23, 2026. The company reported CHF1.062 earnings per share for the quarter, missing the consensus estimate of CHF1.48 by -CHF0.418.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Annually dividend of CHF0.35 which represents an annual dividend yield of 0.22%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 2.09.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.062 in its last earnings report, missing expectations of CHF1.48. Following the earnings report the stock price went down -2.729%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
GALD Stock 12 Month Forecast
Average Price Target
CHF200.60
▲(16.90% Upside)